Only two virus-neutralizing peptide microantibodies (MicroAbs) have been described and little is known about their mode of action. This report concerns a 17 amino acid cyclized MicroAb, derived from the third complementarity-determining region of the heavy chain of MAb F58 (IgG1), that recognizes the same minimum epitope in the V3 loop of the gp120 envelope protein of human immunodeficiency virus type 1 (HIV-1) as the MAb. The MicroAb was able to bind to and neutralize free virus particles. It was up to 5-fold more efficient in mass terms than F58 IgG and its neutralization rate on a molar basis was only 32-fold lower. The mechanism of neutralization of the MicroAb was also investigated. A high level of neutralization (99 %) occurred without any significant decrease in attachment of virus to target C8166 cells. Neutralized virus attached to CD4, the HIV-1 primary receptor. Fusion of virions to cells was partially inhibited by the MicroAb, whereas F58 IgG has been shown to inhibit fusion significantly. Thus, neutralization by the MicroAb appears to be mediated, at least in part, by inhibition of fusion. Control peptides, in which the tyrosine at position 5 or 6 was deleted or changed to phenylalanine, showed no antiviral activity, attesting to the specificity of interaction of the MicroAb with the virion. It therefore appears that the MicroAb acts like an immunoglobulin. The data also show that the MicroAb/MAb F58 epitope on the V3 loop is not involved in attachment of virus to CD4 but is required for subsequent events in early infection.
Introduction
The variable (V) region of each light (L) and heavy (H) chain of an immunoglobulin contains three complementaritydetermining regions (CDRs) that together form the paratope or antigen-binding site. In an anti-lysozyme IgG, 17 amino acid residues of the paratope make contact with 16 residues of the epitope and contribute to the binding energy (Amit et al., 1986) . Progressively smaller derivatives of IgG retain at least some degree of antigen binding, e.g. F(abh) # , Fab, Fv, singlechain Fv and dAb (single V H domains) (Winter & Milstein, 1991 ; de Kruif et al., 1996) . Single-chain antibodies consisting of fused V L and V H regions that include all CDRs bind to and Author for correspondence : Nigel Dimmock.
Fax j44 1203 523568. e-mail nd!dna.bio.warwick.ac.uk inhibit the activity of a variety of virus proteins, including human immunodeficiency virus type 1 (HIV-1) Tat (Mhashilkar et al., 1994) , integrase (Levy-Mintz et al., 1996) and reverse transcriptase (Shaheen et al., 1996) . Another single-chain antibody binds to foot-and-mouth disease virus particles but has little antiviral activity (Mason et al., 1996) . In addition, single-chain antibodies can be expressed intracellularly, and thus can react with antigens that are normally unavailable (Mhashilkar et al., 1994 ; Levy-Mintz et al., 1996 ; Shaheen et al., 1996) , or as fusion proteins on the surface of retroviruses in order to target gene delivery vectors to a specific cell type (Somia et al., 1995 ; Chu & Dornburg, 1997) .
Even smaller fragments, equivalent to a single CDR (that we are calling here microantibodies, or MicroAbs), can have nM antigen-binding activity (Ward et al., 1989) and may be inhibitory if they bind to the active site of toxins, enzymes or receptors. For example, a peptide derived from the CDR-L2 of an anti-reovirus receptor MAb contains sequences shared with the viral receptor protein (Williams et al., 1988 (Williams et al., , 1989 , while peptides from the CDR-H3s of two anti-fibrinogen receptor MAbs contain sequences that mimic the receptor recognition domain in fibrinogen (Jarrin et al., 1994 ; Taub et al., 1988) . However, with regard to antiviral activity, the binding of a whole immunoglobulin, let alone a peptide, to a structure as large as a virus particle does not necessarily mean that there will be neutralization of infectivity (Dimmock, 1993) . What matters is the precise site to which the antibody binds. So far, only two MicroAbs have been reported that have antiviral activity. The first is a 17 amino acid peptide derived from the CDR-H3 of the murine monoclonal IgG1 F58 that competes with F58 for the V3 loop sequence IXXGPGRA from the gp120 of HIV-1 (Levi et al., 1993 ; Fontenot et al., 1996) . F58 was raised against gp120 obtained from cultures infected with HIV-1 IIIB and neutralized nine of eleven primary strains of European or American origin. More recently, a 23 residue MicroAb that neutralizes respiratory syncytial virus and protects mice from infection was described (Bourgeois et al., 1998) . Levi et al. (1993) made a series of peptides encompassing the CDR-H3 variable and Nh-flanking sequences of F58. Cyclization through the terminal cysteines dramatically increased the binding activity of some of these peptides to gp120, possibly by stabilizing a β-turn that is present in CDR loops in native IgG. Preliminary evidence of the antiviral activity of CDR peptides has been presented (Levi et al., 1993 ; Fontenot et al., 1996) . Cyclized peptides had greater antiviral activity than linear peptides, reflecting epitope binding, possibly brought about by prevention of syncytium induction and cell-to-cell spread of virus rather than neutralization of free virions (Levi et al., 1993) . Here, the mechanism of action of the 17 amino acid cyclized peptide MicroAb CDR-H3\C1 has been investigated. It bound directly to and neutralized free virions, and did so with a mass efficiency that exceeded that of its parental IgG. Evidence of its mode of action is presented and we conclude that the MicroAb acts like an immunoglobulin.
Methods
Cells. The CD4 + human T cell lines C8166 and H9 (MRC AIDS Reagent Project) and the CD4 − T cell line A2.01 were grown in RPMI-1640 (Gibco BRL) supplemented with 10 % heat inactivated foetal calf serum, -glutamine (2 mM), penicillin (100 U\ml) and streptomycin (100 µg\ml).
Viruses. HIV-1 B clade strains IIIB, RF, MN, HXB-2D (a molecular clone of IIIB) and the unclassified CBL-4 (Goudsmit et al., 1990) were obtained from the MRC AIDS Reagent Project. These were propagated by co-cultivating chronically infected H9 cells and uninfected H9 cells. Cells were placed in fresh medium 48 h before harvesting, in order to maximize virus load while minimizing the presence of free viral proteins. Tissue culture fluids (TCFs) were centrifuged to remove cells and debris and, when required, virus was purified further as described below. Infectivity was measured in the quantitative syncytium assay in C8166 cells after incubation for 3 days (McLain & Dimmock, 1994) . Typically, titres were derived from dilutions that produced around 50 syncytium forming units (s.f.u.) per well.
Antibodies and peptides. The mouse monoclonal IgG1 MAb F58 (A H kerblom et al., 1990) was purified from TCF using Protein A-Sepharose CL-4B (Sigma) and concentrations were estimated by measuring absorbance at 280 nm. CDR-H3\C1 is a chemically synthesized 17 amino acid cyclized peptide (Euro-Diagnostics) that has 13 residues from the CDR-H3 of F58, three framework residues and an extra cysteine at the C terminus (CDLIYYDYEEDYYFDYC ; Levi et al., 1993) . Purity was 95 % by mass spectroscopy. Control peptides included C8029, which lacked Y5 or Y6, and peptides having Y5 F or Y6 F. Some MicroAb neutralizing activity was lost at k70 mC, resulting in minor variations in specific activity.
Neutralization assays. MicroAb or antibodies were incubated with 1000 s.f.u. HIV-1 in 1 ml for 1 h at 37 mC. This was then added to 2i10& C8166 cells, from a culture that had been split the previous day, for 1 h at 37 mC. Cells were washed to ensure that antiviral activity was the result of interaction with the inoculum and not its progeny, resuspended in 1 ml medium and dispensed into five wells of a 96-well plate. Percentage neutralization was determined either by the syncytium assay (above), by measuring viral p24 in TCF by capture ELISA (see below) or by assaying for infectious progeny virus by the syncytium assay. TCFs were clarified by low-speed centrifugation before carrying out the latter assays.
Neutralization assay in the absence of free MicroAb. Dilutions of MicroAb were incubated with 4i10% s.f.u. HIV-1 HXB-2D for 1 h at 37 mC. An aliquot was retained to determine neutralization. The rest was centrifuged through 3n5 ml 10% (w\v) sucrose in Tris-buffered saline (TBS ; 0n14 M NaCl, 0n02 M Tris buffer, pH 7n6) in a swing-out rotor at 155 000 g for 1 h at 4 mC in order to separate virus or virus-MicroAb complexes from free MicroAb. The supernatant was carefully removed and the virus pellet was resuspended and its infectivity determined. IgG and MicroAb were not pelleted under these conditions. Kinetic neutralization assays. The rate of neutralization was determined by assaying the loss of infectivity over time (Dulbecco et al., 1956) . Virus (1n2i10$ s.f.u.\ml) was mixed with MicroAb or antibody and incubated at 37 mC. At intervals, an aliquot was removed and infectivity assayed. After the adsorption period, the inoculum was removed and the cells were given fresh medium, so the amount of residual antibody was insignificant. The neutralization rate constant (kk neut ) was calculated using the equation below :
where V ! is the infectivity titre at time zero, V t is the titre after incubation for time t at 37 mC and D is the reciprocal of the molar concentration of antibody.
Biostability of MicroAb. MicroAb in cell culture medium was incubated at 37 mC. Neutralizing activity was then determined and the half-life was interpolated by plotting neutralization against time.
Assay for post-attachment neutralization (PAN). C8166 cells (2i10&) were incubated with 2000 s.f.u. HIV-1 in 500 µl medium for 2 h at 21 mC. These conditions gave maximum attachment of virus to cells with the minimum of fusion. After washing, cells were resuspended in MicroAb and incubated at between 4 and 37 mC for 2 h. One half of each sample was washed. Cells were then dispensed into five wells in a 96-well plate and incubated at 37 mC and infectivity was determined. A standard neutralization assay was carried out in parallel. The time taken for virus to become refractory to neutralization at 37 mC was also determined. Virus was incubated with cells at 21 mC, unbound virus was removed by CCG washing and the temperature was raised to 37 mC. MicroAb was added at various times after the temperature shift. After 2 h, free MicroAb was removed, cells were aliquoted and infectivity was determined.
Detection of virion progeny p24 protein in cell lysates. Cell pellets were lysed with 1 % Empigen detergent (Sigma) in PBS at 56 mC for 1 h and allowed to react with solid-phase anti-p24 antibody (D7320 ; Aalto Bioreagents) at room temperature overnight. Recombinant p24 (MRC AIDS Reagent Project) was used as a standard when required. Wells were washed and a positive reaction was detected as described by McInerney et al. (1997) . Typically, A %!& values in the region of 0n5 were obtained with backgrounds of 0n1.
Attachment of virus to C8166 target cells and the effect of MicroAb. Virus was purified on columns of Sephacryl S-1000 (Pharmacia Biotech) . Virus (2i10% s.f.u.) was allowed to attach to 10' C8166 target cells for 2 h at 21 mC. Unattached virus was removed by centrifugation and cell pellets were washed. Cells were lysed with 1 % Empigen and attachment of virions was determined by p24 ELISA. In these assays, virus controls gave A %!& readings around 0n4 with a background of 0n1. The effect of MicroAb on the attachment of virus to cells was determined by pre-incubating MicroAb (200 µl) with virus for 1 h at 37 mC prior to the addition of cells. The amount of neutralization in each sample was determined by culturing an aliquot of virus-inoculated cells for 3 days before counting syncytia. FACS analysis to show the effect of neutralizing antibody on the attachment of virus to C8166 cells, and demonstration that neutralized virus bound to CD4 receptors. Fc receptors on C8166 cells were blocked with normal and heat-complexed rat IgG (McInerney et al., 1997) . Purified virus (2i10% s.f.u.) or virus neutralized with MicroAb was incubated with 10' cells for 2 h at 4 mC. Cells were washed, fixed and permeabilized in methanol overnight at k20 mC. After rehydration and blocking in 10 % heat-inactivated horse serum, cells were incubated successively with sheep anti-p24 serum (1 µg\ml ; D7320), biotinylated donkey anti-sheep antibody and streptavidin-fluorescein. Bound virus was detected by using a Becton Dickinson FACStar. To test the specificity of attachment, cells were incubated with an anti-CD4 MAb, Q4120 (Healy et al., 1990) , that prevents the attachment of virus to the CD4 primary virus receptor.
Fusion of HIV-1 virions with cells, as measured by R18
fluorescence dequenching, and the effect of neutralizing antibody. Concentrated virus was labelled with 800 µl 86 µM octadecyl rhodamine B chloride (R18, Molecular Probes) and free R18 was separated from virus by pelleting through 20 % sucrose, as described by McInerney et al. (1997) . There was a 4-fold loss of infectivity. Solubilization of virus in Triton X-100 gave a 41-fold increase in fluorescence. R18-labelled HIV-1 or neutralized (1 h at 37 mC) R18-labelled HIV-1 (6i10% s.f.u.) was mixed with 3i10' C8166 cells and incubated at 37 mC. At intervals, aliquots of 1i10' cells were removed, a sample was taken to determine the amount of neutralization and paraformaldehyde was added to the remainder to 2 %. Fluorescence was determined with a Becton Dickinson FACStar.
HIV-1-induced cell-cell fusion and the effect of neutralizing MicroAb. C8166 cells were infected with HIV-1 (1 s.f.u. per 200 cells) and incubated for 3 days at 37 mC. These cells (2i10%) were then added to non-infected C8166 cells (2i10&). Incubation was continued for 3 h at 37 mC to allow fusion to take place. Samples were fixed and stained with 1 % methylene blue and 0n25 % pararosaniline (Sigma) in methanol. Fused cells had a mean of 3n5 nuclei (1000 cells per sample). Percentage fusion was calculated as the number of syncytia\total number of cells counted, after subtracting the number of spontaneously fused cells. The anti-fusion activity of MicroAb was determined by adding to infected cells for 1 h at 37 mC before proceeding as described above. Neutralization assays on free virus were carried out in parallel with the same dilutions of MicroAb.
Results

Neutralization by syncytium-inhibition, inhibition of p24 production and inhibition of infectious progeny production
Titrations of MicroAb are shown in Fig. 1 (a-d) . Concentrations that gave 50 % (N &! ) and 90 % (N *! ) neutralization were calculated by regression analysis (Table 1) . N &! for the inhibition of production of infectious HXB-2D progeny was 0n8 µg\ml (Fig. 1 c) , which was about 3-fold more sensitive than assays of the inhibition of syncytium formation (N &! l 2n5 µg\ml ; Fig. 1 a) and the inhibition of production of p24 antigen (N &! l 2 µg\ml ; Fig. 1 b) . Fig. 1 (e) shows neutralization by the parental F58 IgG, assayed by syncytium inhibition and inhibition of infectious progeny production, for comparison. The latter gave an N &! of 2n0 µg\ml (10 nM). At its best, the MicroAb neutralized more efficiently in mass terms than MAb F58 (over 5-fold lower N *! in the assay for inhibition of production of infectious progeny) but was 12-fold less efficient in molar terms. The MicroAb also neutralized clade B strains RF (N &! l 1n05 µg\ml) and MN (N &! l 3 µg\ml) to a similar extent to the non-cloned IIIB strain (N &! l 0n9 µg\ml) (Fig. 1 d) . HXB2-D and MN have the optimum V3 loop tip sequence (IXXGPGRA), while RF has a V instead of A, a conservative change. HIV-1 CBL-4 was poorly neutralized (N &! l 100 µg\ml), although its V3 loop tip sequence (GXXGPGRA) differs only by the substitution of G for I (Goudsmit et al., 1990) . As free MicroAb or MAb were removed in all these assays after virus or virus-antibody complexes had been incubated with cells, it seems that the neutralization obtained was not against progeny virus, as proposed by Levi et al. (1993) . The control peptide C8029, lacking Y5 or Y6, was used at all concentrations employed in Fig. 1 (a-d) and had no antiviral activity. The other control peptides, having Y5 F or Y6 F, also did not neutralize (data not shown). Thus, the overall charge was the same for the all peptides used in this study and was not responsible for neutralization.
Neutralization of HIV-1 in the absence of free MicroAb
Previously published work suggested that the MicroAb acted by preventing cell-to-cell spread of progeny virus (Levi et al., 1993) . To test this, we investigated whether the MicroAb was able to act on free virus. Accordingly, virus and MicroAb were incubated together and then putative virus-MicroAb complexes were separated from free MicroAb by centrifugation through sucrose. Fig. 2 (a) shows that the extent of neutralization (N &! l 1n5 µg\ml ; N *! l 63 µg\ml) was similar to that achieved when free MicroAb and virus were not CCH N. A. C. Jackson and others N. A. C. Jackson and others measured by (a) syncytium-inhibition (N, r l 0n95 ; non-neutralizing peptide C8029, 4); (b) inhibition of p24 production (, r l 0n86 ; non-neutralizing peptide C8029, 4); (c) inhibition of infectious progeny (, r l 0n98 ; non-neutralizing peptide C8029, 4). (d) Neutralization measured by syncytium-inhibition of strains IIIB (N ; r l 0n86), RF ( ; r l 0n94), MN (5 ; r l 0n98) and CBL-4 ( ; r l 0n95), and by non-neutralizing peptide C8029 (4). Inset : gp120 sequences from the tip of the V3 loop.(e) Neutralization of HXB-2D by F58 IgG1 measured by syncytium-inhibition ( ; r l 0n98) and infectious progeny (N ; r l 0n94) assays. Data shown are the means of at least two experiments.
Table 1. Neutralization concentrations for the MicroAb and the monoclonal IgG F58
Neutralization was determined by syncytium-inhibition assay (a), p24-inhibition assay (b) or infectious progeny-inhibition assay (c). Concentrations are given in µg\ml and (in parentheses) µM. N &! and N *! are the concentrations giving 50 and 90 % neutralization. , Neutralization was not achieved.
MicroAb
F58 IgG1
Constant
CCI Neutralization of HIV-1 by a microantibody Neutralization of HIV-1 by a microantibody
Virus control = 12900 sfu/ml Virus control = 8000 sfu/ml Virus control = 4300 sfu/ml Virus control = 37000 sfu/ml Virus control = 5000 sfu/ml Virus control = 2000 sfu/ml 
Irreversibility of neutralization
Since the MicroAb represents only one of the CDRs of MAb F58, we suspected that the MicroAb might be of low affinity and readily dissociate from virus, with resulting loss of neutralization. This was investigated by incubating virusMicroAb complexes that had been separated from free MicroAb for up to 5 h at 37 mC. Virus-MAb F58 IgG complexes were prepared in the same way. No loss of neutralization by either MicroAb or F58 was seen over this period, although there was progressive loss of infectivity in the virus controls through thermal inactivation (Fig. 2 b) . These data suggest either that the MicroAb has a low off-rate (k d ) and a high overall affinity, or that it has a high off-rate and causes irreversible neutralization. Further work is needed to resolve this matter.
Kinetics of neutralization
Neutralization by the MicroAb proceeded without a lag by pseudo-first order kinetics and was biphasic, with a slower second phase (Fig. 3 a) . The average neutralization rate constants (kk neut ) for the first and second phases were 2n4i10$ M −" s −" and 6n8i10# M −" s −" , respectively. Neutralization kinetics of the parental MAb F58 were similarly pseudo-first order and biphasic, with kk neut for the first and second phases of 7n6i10% M −" s −" and 1n6i10% M −" s −" , 32-fold and 24-fold greater, respectively, than the values for the MicroAb (Fig. 3 b) .
Post-attachment neutralization (PAN)
PAN is the neutralization of virus that has already attached to a cell. IgGs that neutralize free HIV-1 virions vary greatly in their ability to give PAN, some acting at any temperature up to 37 mC up to the moment virus fuses with the cell, some only at temperatures of 24 mC and above and some giving no PAN at all .
(i) Effect of temperature. Virus was first permitted to attach to cells at 21 mC for 2 h and then the MicroAb was added in medium at the required temperature for 1 h. Cultures were then incubated at 37 mC without further treatment, or washed to remove unbound antibody (PAN-with-washing), after which fresh medium was added before incubation at 37 mC. Both were then incubated to allow development of syncytia and determination of the extent of neutralization. Fig. 4 (a) shows that PAN and PAN-with-washing at 37 mC gave almost as much neutralization (71 and 72 %, respectively) as did standard neutralization (79 %), where virus and MicroAb were mixed before inoculation onto cells. However, PAN fell to 52 % and PAN-with-washing fell to 23 % when the temperature of virusantibody incubation was lowered to 4 mC, whereas standard neutralization was unaffected (78 %). The PAN-with-washing experiment supports the conclusion reached above that MicroAb acts on the infecting virus and not on the progeny virus. The control peptide C8209 gave no PAN in any of these experiments (data not shown).
(ii) Time required to escape from PAN. Virus becomes refractory to PAN when viral and cell membranes fuse or when it achieves an intermediate stage that either prevents the attachment of antibody or abolishes the neutralization event. In our system, it takes about 90 min for 50 % of attached virus to fuse to cells . The PAN procedure above was modified by warming infected cells to 37 mC and incubating for increasing periods before adding the MicroAb. Fig. 3 . Kinetics of neutralization of HIV-1 HXB-2D by 1n0 µg/ml MicroAb (a) and 1n5 µg/ml F58 IgG1 (b), as measured by syncytium inhibition. Mixtures were incubated at 37 mC. There was no loss of infectivity in a virus control incubated in parallel. Neutralization is expressed as log 10 (V t /V 0 ), where V 0 is the virus titre at time zero and V t the virus titre at time t. Data shown are representative of two experiments. Assays were the means of five replicates. . For PAN, virus was first allowed to attach to cells at 21 mC for 2 h and then, after washing, dilutions of MicroAb were added for a further 2 h at a range of temperatures. Cells were then incubated without washing (shaded bars) or washed to remove excess inoculum (PAN-with-washing ; solid bars) before determining neutralization by syncytium inhibition. Mean neutralization at 10 µg/ml MicroAb is expressed as a percentage of the virus control. Data shown are the means of at least two experiments. (b) Kinetics of PAN by MicroAb at 37 mC. Virus was bound to cells at 21 mC as described above and cells were washed and placed at 37 mC. MicroAb (30 µg/ml) was added to the cells at various times after the temperature shift and assayed as above. The mean neutralization of three experiments is expressed as a percentage of the virus control. Error bars are 1 SD ; if not shown, the SD was within the symbol. Fig. 4 (b) shows that 50 % of virus became refractory to neutralization after 10 min and 90 % after 40 min. The control peptide C8029 gave no neutralization (data not shown). Thus, the factor limiting PAN does not appear to be fusion. Rather, it is likely that the temperature dependence of PAN is due to changes that take place following the initial virus-cell interaction (see Discussion).
Thermal stability of neutralizing activity
MicroAb was incubated in medium at 37 mC and, at intervals (0, 72 and 168 h), was titrated for neutralizing activity (Fig. 5) . The half-life of neutralization activity was calculated to be 92 h (3n8 days) (Fig. 5 inset) .
Mechanism of neutralization
In our earlier work McInerney et al., 1997 ; unpublished data) we investigated seven monoclonal antibodies and determined whether the amount of neutralization of HIV-1 IIIB, or its molecular clone HXB2-D, in C8166 cells was accounted for by the amount of observed inhibition of attachment of virus to target cells or by the observed inhibition of fusion of virus to target cells. From these studies, we found only one antibody (F105) that neutralized by inhibiting attachment of virus to target cells. The rest did not inhibit attachment at concentrations that gave significant neutralization. Of these MAbs, three appeared to neutralize by inhibiting the fusion of viral and cell membranes and one of these was F58, from which the MicroAb was derived . The remaining three antibodies did not inhibit fusion and by inference it was concluded that these neutralized by inhibiting a post-fusion event.
CDA Fig. 5 . Stability of the neutralization activity of MicroAb incubated at 37 mC in TCF supplemented with 10 % foetal calf serum. Dilutions of MicroAb were incubated for 0 ( ; r l 0n97), 72 (N ; r l 0n94) and 168 h (5 ; r l 0n99). The residual neutralization activity of the MicroAb was then measured by the syncytium-inhibition assay. Inset : calculation of the half-life of neutralizing activity from a plot of the concentration of MicroAb needed for 50 % neutralization for each sample against time (r l 0n99).
(i) MicroAb does not neutralize by inhibiting attachment of virus to the target cell. The attachment of virus to C8166 cells was demonstrated by labelling virion p24 with specific antibody followed by FACS analysis (Fig. 6 a) . Neutralization by the CD4-binding site-specific human monoclonal IgG1 F105 is paralleled by inhibition of attachment of neutralized virus to target cells (McInerney et al., 1997 ; Posner et al., 1991) , and was used as a positive control (Fig. 6 b) . However, virus that was neutralized to the same extent by MicroAb (90 % loss of infectivity) attached to C8166 cells as efficiently as nonneutralized virus (Fig. 6 c) . The control peptide C8029 also had no effect on the attachment of non-neutralized virus to C8166 cells (Fig. 6 d) . The anti-CD4 MAb Q4120, which blocks attachment of infectious virus to C8166 cells (Healy et al., 1990 ; McInerney et al., 1997) , also inhibited the attachment of MicroAb-neutralized virus, indicating that the complex was binding specifically to CD4 receptors (data not shown). The above result was confirmed quantitatively by assaying the amount of virion p24 attached to C8166 cells by ELISA. Fig.  6 (e) shows that under conditions that gave 90 % neutralization (16 µg\ml MicroAb), there was no inhibition of attachment of virus to the inoculated C8166 cells. Increasing the concentration of MicroAb 10-fold gave 99 % neutralization but no significant inhibition of attachment of virus to target cells.
(ii) MicroAb partially inhibits virus-cell fusion. The incubation of R18-labelled virus with C8166 cells for 3 h at 37 mC gave a progressive increase of fluorescence (dequenching) (Fig. 7 a) , indicating that fusion of viral and cell membranes had taken place. In contrast, there was no fluorescence dequenching when virus was incubated for the same time with cells lacking the CD4 primary receptor (A2.01 cells ; Fig. 7 c) . In our hands, the monoclonal IgG b12 does not inhibit attachment of neutralized virus to C8166 cells but inhibits fluorescence dequenching (McInerney et al., 1997) . Here, it was used as a positive control and Fig. 7 (d) shows that fluorescence was quenched as fully as when CD4 − cells were used as targets. In contrast, MicroAbneutralized virus gave significant fluorescence dequenching, although this was not as great as in cells inoculated with nonneutralized virus (Fig. 7 b) . This may mean (i) that the fusion efficiency of all neutralized virions was reduced, and that this may have been sufficient to cause the observed 92 % loss of infectivity, or (ii) that fusion of a small proportion of virions was reduced substantially and this was responsible for their loss of infectivity. In this case, the fusion efficiency of the majority of virions would be unaffected and their infectivity would have been lost by the inhibition of a post-fusion event.
(iii) MicroAb partially inhibits virus-mediated cell-cell fusion.
In earlier experiments carried out in our laboratory, concentrations of MAbs that neutralized virus also inhibited cell-cell fusion to a similar extent (e.g. F58, from which the MicroAb was derived, and b12) or neutralized while having no effect at all on cell-cell fusion (ICR41.1i, b12 Fab) McInerney et al., 1997) . However, Fig. 7 (e) shows that the MicroAb caused some inhibition of fusion, which in percentage terms was less than the neutralization observed for all equivalent concentrations of MicroAb. This was an intermediate situation that we had not seen before when studying cell-cell fusion. Non-linear regression analysis was carried out (Fig. 7 e, inset) and shows, for example, that 2 g\ml MicroAb gave 62 % neutralization but only 28 % inhibition of fusion. Increasing the concentration of MicroAb to 60 g\ml gave 99 % neutralization but only 50 % inhibition of fusion. Thus, the data on inhibition of HIV-1-mediated cell-cell fusion mirror closely those described above for virion-cell fusion. 4 s.f.u.) was incubated with MicroAb or C8029 for 1 h at 37 mC. C8166 cells were then inoculated with virus-MicroAb or virus-C8029 mixtures for 2 h at 4 mC. The presence of cell-associated virus was determined by staining with anti-p24 Ig and FACS analysis. Percentage neutralization was determined by culturing a sample of cells removed from mixtures before fixation and counting syncytia after incubation at 37 mC for 3 days. Data shown are representative of two experiments. (e) ELISA for virion p24. Virus was mixed with various concentrations of MicroAb and incubated for 1 h at 37 mC. Virus or virus-MicroAb mixtures were then incubated with cells for 2 h at 21 mC to determine their ability to attach. Non-attached virus was removed by washing with cold medium. Cells and virus were lysed with Empigen detergent and heat-treated at 56 mC for 1 h. Attached cell-associated virus was quantified by means of an antibody-capture ELISA for viral p24 antigen (bars). Aliquots of all the virus-MicroAb mixtures were assayed to determine the percentage neutralization (N). Data shown are representative of two experiments.
Discussion
In their original report, Levi et al. (1993) concluded that the MicroAb based on the CDR-H3 sequence of a V3 loop-specific IgG ' prevented syncytium induction by inhibiting cell-to-cell spread of virus rather than by neutralizing free virions. ' It is now clear from our data, in which putative virus-MicroAb complexes were separated from free MicroAb before inoculation onto target cells, that the MicroAb is able to neutralize free virions. This view is supported by the PANwith-washing experiments, where MicroAb was removed after interacting with virus for 1 h (Fig. 4 a) , and neutralization assays (Fig. 1) , where free MicroAb was removed after virus had attached to cells. In addition, recent mass spectrometry epitope-mapping studies have demonstrated that the MicroAb and MAb F58 have the same minimum epitope (RKXXXIXX-GPGR in IIIB and its clones and RKXXXIGPGR in MN and RF ; Millar et al., 1998) . MicroAb also neutralized efficiently : 50 % neutralization at 0n8 µg\ml and 90 % neutralization at 7n5 µg\ml, in an assay that measured the production of progeny virions. All three of our assays gave a higher specific activity than previously reported (Levi et al., 1993) . MicroAb was 100-fold more neutralizing than the 60 amino acid triplet repeat MicroAb that included its IYYDYEED sequence (Fontenot et al., 1996) . In our most sensitive assay, MicroAb gave 90 % neutralization at a 5-fold lower concentration on a mass basis than F58 IgG (Table 1 ). The MicroAb peptide was not cytotoxic or cytostatic, as high concentrations failed to inhibit strain CBL-4 (Fig. 1 d) , and neutralized when the only MicroAb present was that bound to the virion (Fig. 2 a) . The control peptide C8029 had the same charge as the MicroAb and differed by only one amino acid residue, yet had no antiviral activity, thus demonstrating the specificity of neutralization by the MicroAb. A conservative substitution of Y5 F or Y6 F in other peptides did not restore neutralizing activity.
Kinetics of neutralization were pseudo-first order and biphasic, like those of the parent MAb F58. Some HIV-1 neutralizing antibodies, such as b12 (a human IgG1), have pseudo-first order kinetics and are monophasic (McInerney et al., 1997) , while others have multi-hit kinetics and are monophasic or biphasic (McLain & Dimmock, 1994 ; Krause et al., 1997) . The reason for the biphasic curve is unclear, especially as the MicroAb was 95 % pure by mass spectrometry and the virus (HXB-2D) was derived by a single passage from a molecular clone. One explanation is that a mutant population has grown up, so that only approximately 0n25-0n4 log "! of the virus is neutralized efficiently (Fig. 3) . However, it is unlikely that this would be uniformly mutated within a single epitope, and such a situation was not seen with MAb b12 (McInerney et al., 1997) . A second possibility is that there are two separate neutralization events with different kinetics proceeding simultaneously, with the faster event neutralizing only 0n25-0n4 log "! of the virus. The rate of CDC Neutralization of HIV-1 by a microantibody Neutralization of HIV-1 by a microantibody (e) HIV-1-mediated cell-cell fusion. C8166 cells were infected with HIV-1 HXB-2D and incubated for 72 h at 37 mC. Various concentrations of MicroAb were added for 1 h at 37 mC and the ability of MicroAb-treated infected cells to fuse was measured by incubating with non-infected C8166 cells for 3 h at 37 mC. Cells were fixed and syncytia counted. The percentage inhibition of fusion relative to the virus control without MicroAb is presented (bars). The ability of the MicroAb to neutralize virions was measured at the same time by the standard syncytium-inhibition assay (N). C8029 non-neutralizing peptide was used at 60 µg/ml. Inset is a non-linear regression analysis of the data to permit calculation of the 50 % fusion-inhibitory and neutralizing concentrations. Data shown are the means of three experiments.
N. A. C. Jackson and others N. A. C. Jackson and others neutralization of the MicroAb (kk neut ) was 2n4i10$ M −" s −" , approximately 32-fold less than that of the parental IgG, but impressive for a molecule of 17 amino acid residues and with 2 % of the mass of IgG. The kk neut of the MicroAb is close to the kk neut of the HIV-1-specific IgGs ICR39.13g and ICR41.1i and 5-fold higher than that of IgG ICR39.3b (McLain & Dimmock, 1994) . What needs to be determined now, in order to understand the neutralization mediated by the MicroAb better, is the number of molecules per virion. The other issue addressed in this report is the mechanism by which the MicroAb kills HIV-1. Firstly, it is clear that the MicroAb can neutralize 90 % infectivity without inhibiting attachment of neutralized virus to the target cells detectably (Fig. 6 ) and that the MicroAb is able to neutralize virus efficiently that is already attached to cells (Fig. 4) . In these ways, the MicroAb behaves like the parental MAb F58 . Neutralization resulting from inhibition of attachment of virus to the target cell is relatively rare and only one of eight antibodies that we have studied (including the MicroAb) neutralizes in this way. However, in other experimental systems, in which different virus strains and cells were employed, MAbs may neutralize by inhibiting virus attachment (Ugolini et al., 1997 ; Valenzuela et al., 1997) . In our system, MAb F105 (Posner et al., 1991) , which is specific to the CD4-binding site region, co-ordinately neutralizes and inhibits attachment of neutralized virus to the target cell and is an invaluable positive control (Fig. 6 b ; McInerney et al., 1997) . Among the antibodies that do not inhibit attachment to the target cell are three that are also specific to the CD4-binding site region, as defined by inhibition of gp120 attachment to soluble CD4. Presumably, such antibodies do not actually obstruct the binding of CD4 to the CD4-binding site or they neutralize at a low ratio of antibody molecules to virion gp120 and thus permit CD4 to attach to gp120 that is unencumbered with antibody. The assay used to define the CD4-binding site presumably requires a stoichiometry of one antibody molecule per soluble gp120 molecule and therefore should not be extrapolated to virions, which have 72 oligomeric gp120 molecules.
Whereas neutralization and inhibition of virus-mediated fusion by MAb F58 proceed quantitatively in parallel, and it is reasonable to assume a causal relationship , the situation with the MicroAb is less clear cut. The MicroAb gave significant neutralization without a complete loss of virion-cell or cell-cell fusion activity (Fig. 7) . The interpretation of these data is problematic and depends on whether a virion with reduced fusion efficiency (reduced fluorescence dequenching) is fully neutralized. Alternatively, fusion by the majority of virions may be unaffected, while fusion of a small proportion of virions is completely eliminated. It is noteworthy that F58 IgG is bivalent and its MicroAb is monovalent, which may alter their mode of neutralization radically, as was observed with b12 IgG (fusion-inhibiting) and b12 Fab (not fusion-inhibiting) (McInerney et al., 1997) .
The ability to give PAN confirms that the MicroAb can neutralize by inhibiting a post-attachment step. Experiments in which addition of the MicroAb was delayed give an insight into the virus-cell interaction, since 50 % of virus became resistant to neutralization after only 10 min. This was not due to virion-cell membrane fusion, since 50 % fusion takes about 90 min . It may be that the epitope becomes unavailable or that the virus has completed the process that is inhibited by the antibody, so that it can no longer be neutralized. One such event might be interaction of the V3 loop with a co-receptor (Weiss & Clapham, 1996) . It is potentially important to protection in vivo that neutralizing IgGs vary greatly in their ability to give PAN. Of four neutralizing IgGs tested, two (ICR39.13g and b12) give PAN at 37 mC, probably until fusion takes place, but the other two (ICR39.3b and ICR41.1i), like the MicroAb, can give PAN only during a narrow window of time unpublished data) .
Our studies also add to an extensive literature on the involvement of the V3 loop in virus entry. After virus binds to CD4, the V3 loop undergoes conformational changes that result in its increased exposure (Sattentau, 1998) . Neutralization and inhibition of fusion by the MicroAb confirm the involvement of the V3 loop tip region (RKXXXIGPGR ; Millar et al., 1998) in an essential post-CD4-binding stage in infection, possibly co-receptor binding. In particular, the kinetics of PAN by both the MicroAb and its parent MAb F58 suggest that 50 % of the epitope becomes inaccessible within 10 min of attachment of virus to cells at 37 mC. This is consistent with the suggestion that evasion of the antibody response by the virus is mediated in part by steric constraints imposed on the coreceptor binding site following CD4 binding (Moore & Binley, 1998) .
Finally, it is possible that the small MicroAb can achieve greater tissue penetration than whole immunoglobulins and may be of use in immunotherapy and immunoprophylaxis against a variety of infectious agents and neoplasms or as a diagnostic aid for imaging in vivo. MicroAbs may even be the type of small molecule that Sattentau (1998) suggests is needed to solve the problem of the steric exclusion of IgG from the virions of primary HIV-1 isolates. Indeed, the half-life of the MicroAb (nearly 4 days ; Fig. 5 ) indicates that it may be stable enough for these purposes. However, much remains to be determined before the clinical potential of MicroAbs can be assessed.
